Literature DB >> 20046626

Evaluation of laboratory methods to improve characterization of dogs with von Willebrand disease.

Hilary J Burgess1, J Paul Woods, Anthony C G Abrams-Ogg, R Darren Wood.   

Abstract

The objective of the study was to investigate the value of additional tests [platelet count, partial thromboplastin time (PTT), platelet function analysis using the PFA-100, Collagen binding assay (vWF:CBA), and Factor VIII activity], for use in conjunction with the von Willebrand factor antigen enzyme-linked immunosorbent assay (ELISA), as part of a newly developed diagnostic profile for improved characterization of patients with von Willebrand disease (vWD). The study population included 183 clinically healthy canines ranging in vWF:Ag concentration from 1% to 125%. The Asserachrom vWF:Ag ELISA assay was used as an external control for the determination of vWD status. Degree of association between the additional tests and vWF concentration was evaluated, and associations between the additional tests were also assessed, including their ability to distinguish dogs with vWD from those without vWD. In addition, a reference interval was determined for the PFA-100 platelet function analyzer. Strong associations were found between the PFA-100, vWF:CBA, and Asserachrom vWF:Ag assay, and a significant association was found between the PFA-100 and vWF:CBA. An association was detected between Factor VIII activity and the Asserachrom vWF:Ag assay, the vWF:CBA and the PFA-100; however, a corresponding pattern was not visually apparent in the raw data, making the association clinically irrelevant. The association between the platelet count and the PTT with the other additional tests was negligible. Based on our results, the vWF:CBA and PFA-100 would be valuable assets, in conjunction with a vWF:Ag assay, in a canine vWD diagnostic profile to further characterize patients with this disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20046626      PMCID: PMC2757705     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  27 in total

1.  Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options.

Authors:  E J Favaloro
Journal:  Am J Clin Pathol       Date:  2000-10       Impact factor: 2.493

2.  von Willebrand disease phenotype and von Willebrand factor marker genotype in Doberman Pinschers.

Authors:  M B Brooks; H N Erb; P A Foureman; K Ray
Journal:  Am J Vet Res       Date:  2001-03       Impact factor: 1.156

3.  Changes in factor VIII activity and von Willebrand factor antigen concentration with age in dogs.

Authors:  P D Mansell; B W Parry
Journal:  Br Vet J       Date:  1992 Jul-Aug

4.  Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease.

Authors:  Y Buyukasik; S Karakus; H Goker; I C Haznedaroglu; D Ozatli; N Sayinalp; O I Ozcebe; S V Dundar; S Kirazli
Journal:  Blood Coagul Fibrinolysis       Date:  2002-06       Impact factor: 1.276

5.  Determination of von Willebrand factor activity with collagen-binding assay and diagnosis of von Willebrand disease: effect of collagen source and coating conditions.

Authors:  Ryszard Paczuski
Journal:  J Lab Clin Med       Date:  2002-10

6.  Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies.

Authors:  E J Favaloro; G Kershaw; M Bukuya; M Hertzberg; J Koutts
Journal:  Haemophilia       Date:  2001-03       Impact factor: 4.287

Review 7.  Insights from von Willebrand disease animal models.

Authors:  C V Denis; D D Wagner
Journal:  Cell Mol Life Sci       Date:  1999-12       Impact factor: 9.261

Review 8.  von Willebrand's disease in the dog and cat.

Authors:  J S Thomas
Journal:  Vet Clin North Am Small Anim Pract       Date:  1996-09       Impact factor: 2.093

Review 9.  von Willebrand disease: still an intriguing disorder in the era of molecular medicine.

Authors:  F Rodeghiero
Journal:  Haemophilia       Date:  2002-05       Impact factor: 4.287

10.  Assessment of a point-of-care instrument for identification of primary hemostatic disorders in dogs.

Authors:  M B Callan; U Giger
Journal:  Am J Vet Res       Date:  2001-05       Impact factor: 1.156

View more
  5 in total

1.  Use of a questionnaire to predict von Willebrand disease status and characterize hemorrhagic signs in a population of dogs and evaluation of a diagnostic profile to predict risk of bleeding.

Authors:  Hilary J Burgess; J Paul Woods; Anthony C G Abrams-Ogg; R Darren Wood
Journal:  Can J Vet Res       Date:  2009-10       Impact factor: 1.310

2.  Congenital Type III von Willebrand's disease unmasked by hypothyroidism in a Shetland sheepdog.

Authors:  Margaret Scuderi; Lauren Bessey; Elisabeth Snead; Hilary Burgess; Anthony Carr
Journal:  Can Vet J       Date:  2015-09       Impact factor: 1.008

Review 3.  Platelet Function and Therapeutic Applications in Dogs: Current Status and Future Prospects.

Authors:  Laura Cortese; Pete W Christopherson; Alessandra Pelagalli
Journal:  Animals (Basel)       Date:  2020-01-25       Impact factor: 2.752

4.  Comparison of Multiplate, Platelet Function Analyzer-200, and Plateletworks in Healthy Dogs Treated with Aspirin and Clopidogrel.

Authors:  S Saati; A C G Abrams-Ogg; S L Blois; R D Wood
Journal:  J Vet Intern Med       Date:  2017-11-30       Impact factor: 3.333

5.  Heterozygosity testing and multiplex DNA panel screening as a potential tool to monitor health and inbreeding in a small, closed dog population.

Authors:  S F A Keijser; H Fieten; M Vos-Loohuis; C J Piek; H Anderson; J Donner; I Scholten; M Nielen; J W Hesselink; F G van Steenbeek
Journal:  Canine Genet Epidemiol       Date:  2018-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.